Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant

Samantha M. Jaglowski, MD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Thomas S. Lin, MD, PhD, Beth Fischer, Diane Scholl, Patrick Elder, MS, Steven M. Devine, MD, Michael R. Grever, M.D., John C. Byrd, MD, Leslie Andritsos, MD

Blood (2010) 116 (21): 2383.

https://doi.org/10.1182/blood.V116.21.2383.2383

Published: 2010

Journal Articles

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Mitch A. Phelps, Thomas S. Lin, Amy J. Johnson, Eunju Hurh, Darlene M. Rozewski, Katherine L. Farley, Di Wu, Kristie A. Blum, Beth Fischer, Sarah M. Mitchell, Mollie E. Moran, Michelle Brooker-McEldowney, Nyla A. Heerema, David Jarjoura, Larry J. Schaaf, John C. Byrd, Michael R. Grever, James T. Dalton

Blood (2009) 113 (12): 2637–2645.

https://doi.org/10.1182/blood-2008-07-168583

Published: 2009

Journal Articles

Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Thomas S. Lin, MD, PhD, Beth Fischer, BSN, RN, Kristie A. Blum, MD, Pierluigi Porcu, MD, Eric H. Kraut, MD, Robert A. Baiocchi, MD, PhD, Mollie E. Moran, MSN, CNP, Sarah Mitchell, Michael R. Grever, MD, John C. Byrd, MD

Blood (2008) 112 (11): 1571.

https://doi.org/10.1182/blood.V112.11.1571.1571

Published: 2008

Journal Articles

Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Beth Fischer, BSN, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD, Joseph M. Flynn, DO, MPH, Mollie E. Moran, MSN, CNP, Sarah Mitchell, Amy J. Johnson, PhD, Mitch A. Phelps, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2008) 112 (11): 46.

https://doi.org/10.1182/blood.V112.11.46.46

Published: 2008

Journal Articles

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

Leslie A. Andritsos, MD, Beth Fischer, R.N., Thomas S. Lin, M.D., Kristie A. Blum, M.D., Jeffrey A. Jones, M.D., Mollie E. Moran, C.N.P., John C. Byrd, M.D., Michael R. Grever, M.D.

Blood (2007) 110 (11): 3128.

https://doi.org/10.1182/blood.V110.11.3128.3128

Published: 2007

Journal Articles

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD,MPH, Mollie E. Moran, CNP, Sarah Broering, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Larry J. Schaaf, PhD, Linda S. Mahoney, RN, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2007) 110 (11): 3104.

https://doi.org/10.1182/blood.V110.11.3104.3104

Published: 2007

Journal Articles

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Nyla A. Heerema, PhD, John C. Byrd, MD, Leslie A. Andritsos, MD, Gerard Lozanski, MD, Kristie Blum, MD, Beth Fischer, RN, Jeffrey A. Jones, MD, Mollie E. Moran, CNP, Sarah Groering, Larry J. Schaaf, Linda S. Mahoney, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch A. Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Thomas S. Lin, MD

Blood (2007) 110 (11): 3107.

https://doi.org/10.1182/blood.V110.11.3107.3107

Published: 2007

Journal Articles

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Thomas S. Lin, MD, PhD, Mitch Phelps, PhD, James T. Dalton, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Mollie E. Moran, CNP, Michelle B. McEldowney, CNP, Sara Broering, Dimitrios Colevas, MD, John C. Byrd, MD, Michael R. Grever, MD

Blood (2006) 108 (11): 2845.

https://doi.org/10.1182/blood.V108.11.2845.2845

Published: 2006

Journal Articles

Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Mollie E. Moran, CNP, Michelle B. McEldowney, CNP, Sara Broering, Gerard Lozanski, MD, Dimitrios Colevas, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2006) 108 (11): 302.

https://doi.org/10.1182/blood.V108.11.302.302

Published: 2006

Journal Articles

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Blood (2006) 109 (2): 399–404.

https://doi.org/10.1182/blood-2006-05-020735

Published: 2006

Journal Articles

Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule.

Mollie E. Moran, MSN, Beth Fischer, MSN, Sara Broering, BS, Kristie A. Blum, MD, Thomas S. Lin, MD, PhD, John C. Byrd, MD, Michael R. Grever, MD, Michelle Brooker-McEldowney, MSN

Blood (2005) 106 (11): 2124.

https://doi.org/10.1182/blood.V106.11.2124.2124

Published: 2005

Journal Articles

Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Mollie E. Moran, RN, CNP, Maureen M. Buckner, RN, CNP, Roshini Shank, BS, Eric H. Kraut, MD, Pierluigi Porcu, MD, Sherif S. Farag, MD, PhD, Charles F. Eisenbeis, MD, PhD, Dimitrios Colevas, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2005) 106 (11): 944.

https://doi.org/10.1182/blood.V106.11.944.944

Published: 2005

Journal Articles

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia

John C. Byrd, Guido Marcucci, Mark R. Parthun, Jim J. Xiao, Rebecca B. Klisovic, Mollie Moran, Thomas S. Lin, Shujun Liu, Amy R. Sklenar, Melanie E. Davis, David M. Lucas, Beth Fischer, Roshini Shank, Sooraj L. Tejaswi, Philip Binkley, John Wright, Kenneth K. Chan, Michael R. Grever

Blood (2005) 105 (3): 959–967.

https://doi.org/10.1182/blood-2004-05-1693

Published: 2005

Journal Articles

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

John C. Byrd, MD, Thomas S. Lin, MD, Phd, James T. Dalton, PhD, Di Wu, PhD, Beth Fischer, MSN, Mollie E. Moran, CRNP, Kristie A. Blum, MD, Roshini S. Shank, BA, David M. Lucas, PhD, Margaret S. Lucas, PA-C, Jose-Ramon Suarez, MD, Michael R. Grever, MD

Blood (2004) 104 (11): 341.

https://doi.org/10.1182/blood.V104.11.341.341

Published: 2004

Journal Articles

Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Thomas S. Lin, MD, PhD, Beth Fischer, MSN, Mollie E. Moran, CRNP, David M. Lucas, PhD, Roshini S. Shank, BA, Eric H. Kraut, MD, Sheriff S. Farag, MD, PhD, Margaret S. Lucas, PA-C, Alexander D. Colevas, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2004) 104 (11): 2492.

https://doi.org/10.1182/blood.V104.11.2492.2492

Published: 2004

NARROW

Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule.

Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only